Floatz logo

S-65487

Multiple Myeloma (MM)

Novartis PharmaceuticalsSmall moleculePhase 1Dormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

498 Active assets in the Multiple Myeloma (MM) cohort.

Asset / SponsorPhaseRating
FILGRASTIM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Inno-206
University of Arkansas
Phase 3BBB
Hyaluronidase fihj
Massachusetts General Hospital
Phase 4BBB
Busulphan
M.D. Anderson Cancer Center
Phase 4BBB
Filanesib
PETHEMA Foundation
Phase 2BBB

View all 50 →

Same molecule, other indications

S-65487 is also rated in:

acute myeloid leukemiaDormant
C
Indicative ·
34 / 100
View asset →
acute myeloid leukemiaDormant
D
Indicative ·
30 / 100
View asset →
non-Hodgkin lymphomaDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →